DCM
MLYS icon

Driehaus Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Driehaus Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-257,371
Closed -$3.01M – 428
2024
Q2 		$3.01M Buy
257,371
+74,074
+40% +$933K 0.03% 278
2024
Q1 		$2.37M Sell
183,297
-22,968
-11% -$284K 0.02% 298
2023
Q4 		$1.77M Sell
206,265
-295,109
-59% -$2.32M 0.02% 302
2023
Q3 		$4.77M Buy
501,374
+1,391
+0.3% +$18.1K 0.06% 286
2023
Q2 		$8.52M Buy
499,983
+46,982
+10% +$702K 0.11% 229
2023
Q1 		$7.09M Buy
+453,001
New +$7.63M 0.1% 263

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Driehaus Capital Management's MLYS Position: Q3 2024 in Review

Driehaus Capital Management sold out of Mineralys Therapeutics (MLYS) in Q3 2024, closing a stake of 257,371 shares — an estimated $3.01M sold.

Driehaus Capital Management first reported a position in MLYS in Q1 2023 and held it in 6 quarters. The position peaked at $8.52M in Q2 2023. 106 funds tracked by Wall St. Rank hold MLYS as of Q3 2024.

  • Driehaus Capital Management reported no remaining Mineralys Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Driehaus Capital Management sold 257,371 Mineralys Therapeutics shares in Q3 2024, an estimated $3.01M.
  • Driehaus Capital Management first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 6 quarters.
  • Driehaus Capital Management's Mineralys Therapeutics position peaked at $8.52M in Q2 2023.
  • 106 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2024.

Based on Driehaus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.